written by reader $2 covid pharma stock

By chuppy1130, June 4, 2020

Kyle Dennis touting a $2 pharma stock, heavy insider buying from CEO, upcoming FDA catalyst and heavily shorted.

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

11
Share your thoughts...

avatar
4 Comment threads
7 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
6 Comment authors
jazzroxyjazzroxymar LewisGermaine Woodsgkissi Recent comment authors

This site uses Akismet to reduce spam. Learn how your comment data is processed.

jazzroxy
Irregular
👍6
jazzroxy

I have been barraged with emails, but have not been able to figure it out…

gkissi
Member
👍13
gkissi

I’m absolutely convinced this is OPK now! I got the following email from Kyle today:

…Like it or not
The country is going back to work.
Hospitals, universities, businesses, state governments…
We will all need more testing…both PCR and antibody
And that’s what my latest Sniper Report pick excels at…
In April it inked a deal with New York State to test state employees…

Now here’s the headline about that partnership with New York in April:
OPKO Health’s BioReference Laboratories in Partnership with New York State Initiates Testing for COVID-19 Antibodies
Dow Jones 4/29/20 1:35 PM ET

gkissi
Member
👍13
gkissi

I believe he’s talking about OPK (OPKO HEALTH INC). Here’s a headline I found on briefing.com:
Opko Health: FDA has authorized OPKO to undertake a Phase 2 trial with RAYALDEE as a treatment for patients with mild-to-moderate COVID-19. Also a search on openinsider.com shows the CEO heavily buying this stock. The current price as at now is $2.20.

I’m willing to bet this is the stock he’s talking about! But of course this is just my opinion and my own digging after they’ve been pounding me with same emails you’ve been getting.

dacole
Member
👍0
dacole

Sounds reasonable to me.

dacole
Member
👍0
dacole

The redacted Sec Form 4 in the email has identical share numbers for OPK’s June 2nd Sec Form 4

Germaine Woods
Guest
Germaine Woods

It’s OPK … I just checked the SEC website

mar Lewis
Guest
mar Lewis

OPKO Health (NASDAQ:OPK) is a highly shorted stock — 24% of its float is sold short. What this means is that institutions and other investors have borrowed almost a quarter of its shares and sold them on the market, in hopes of being able to profit by repurchasing them later at a lower price. The short-sellers are betting the stock will be lower in the future.

jazzroxy
Guest
jazzroxy

Well today is supposedly the day raging bull, Kyle Dennis, is going to announce his secret pharma stock, which if past history holds true, should bump the shares 10-20% higher, at least short term…what happens after that is anyone’s guess…

jazzroxy
Guest
jazzroxy

Will actually be called out out 10am west coast time… We shall see…I’m already long the stock, but will have my hand on the sell button!!!

jazzroxy
Irregular
👍6
jazzroxy

Well, assuming he published the sniper report, it bumped a little right at 1 ET, but moved back down,,, maybe he doesn’t have many sniper subscribers yet, but I sure didn’t see any major move…